13F Holdings
中文EN

ALZN Alzamend Neuro, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1677077 · Fiscal year ends 04/30

Financial factors as of 2026-07-31 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-45.7%
TTM EPS YoY-72.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-163.2%
ROA-122.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets32.1%
Debt / equity0.00x
Current ratio—
Interest coverage-1,480.55x

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-30.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-04-30FY20252025-04-30FY20242024-04-30FY20232023-04-30FY20222022-04-30
Income statement
Revenue—————
R&D expense$3.63M$1.41M$6.46M$7.45M$5.20M
SG&A expense$5.14M$3.08M$3.48M$7.42M$7.12M
Operating income-$8.77M-$4.50M-$9.94M-$14.87M-$12.32M
Interest expense$6,619$18,029$10,101$7,701$46,524
Pretax income-$8.77M-$4.51M-$9.95M-$14.88M-$12.36M
Net income-$8.77M-$4.51M-$9.95M-$14.88M-$12.36M
EBITDA-$8.66M-$4.45M-$9.89M-$14.85M-$12.32M
EPS (basic)-2.63-11.32-132.33-22.89-0.14
EPS (diluted)-2.63-11.32-132.33-22.89-0.14
Weighted avg. shares (diluted)3.34M450,79974,174650,12689.10M
Balance sheet
Cash & equivalents$710,689$3.95M$376,048$5.14M$14.06M
Current assets$1.76M$4.18M$455,242$5.84M$14.41M
PP&E, net$314,866$425,606$176,346$79,843$102,909
Total assets$2.08M$4.60M$631,588$5.92M$14.52M
Current liabilities———$2.87M$1.16M
Total liabilities$1.35M$634,761$3.23M$2.87M$1.16M
Shareholders' equity$733,211$3.97M-$2.59M$3.05M$13.35M
Shares outstanding4.26M778,73376,444646,26795.48M
Cash flow statement
Operating cash flow-$8.07M-$6.57M-$8.27M-$8.92M-$6.61M
Investing cash flow—-$300,000-$147,243—-$106,458
Financing cash flow$4.83M$10.44M$3.65M$200$18.85M
Depreciation & amortization$110,740$50,740$50,740$23,066$3,549
Stock-based compensation$707,527$325,108$955,633$3.58M$4.41M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.